What is ICON?
Founded in 1990 and headquartered in Dublin, Ireland, ICON offers comprehensive drug and device development and commercialization services. The company serves a diverse clientele, including pharmaceutical, biotechnology, medical device, and government and public health organizations. ICON's expertise spans the entire lifecycle of product development, from early-stage research to market launch and post-market support, positioning it as a critical partner for life sciences innovators seeking to bring new therapies and medical technologies to market.
How much funding has ICON raised?
ICON has raised a total of $49.1M across 1 funding round:
Stock Offering
$49.1M
Stock Issuance/Offering (1998): $49.1M, investors not publicly disclosed
What's next for ICON?
The recent major strategic investment signals ICON's ongoing commitment to expanding its service offerings and global reach. This enterprise-level funding is likely to fuel further advancements in drug and device development technologies, potentially through acquisitions or enhanced R&D initiatives. ICON's strategic focus on supporting pharmaceutical, biotechnology, and medical device companies suggests that future growth will be driven by its ability to adapt to evolving regulatory landscapes and scientific breakthroughs, solidifying its role as a key enabler in the healthcare ecosystem.
See full ICON company page
